User menu

An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).

Bibliographic reference Segaert, Siegfried ; Ghislain, Pierre-Dominique ; Boone, Caroline. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).. In: Journal of Dermatological Treatment, Vol. 27, no.2, p. 103-109 (2016)
Permanent URL http://hdl.handle.net/2078.1/184184
  1. Baker Erica L., Coleman Craig I., Reinhart Kurt M., Phung Olivia J., Kugelman Lisa, Chen Wendy, White C. Michael, Mamolo Carla M., Cappelleri Joseph C., Baker William L., Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses, 10.1007/s13555-012-0009-3
  2. Schmitt J., Rosumeck S., Thomaschewski G., Sporbeck B., Haufe E., Nast A., Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials, 10.1111/bjd.12663
  3. Sandoval Laura F., Pierce Allison, Feldman Steven R., Systemic Therapies for Psoriasis: An Evidence-Based Update, 10.1007/s40257-014-0064-x
  4. Semble Ashley L., Davis Scott A., Feldman Steven R., Safety and Tolerability of Tumor Necrosis Factor-α Inhibitors in Psoriasis: A Narrative Review, 10.1007/s40257-013-0053-5
  5. European Medicines Agency, Enbrel: procedural steps taken and scientific information after the authorisation (2014)
  6. Tyring Stephen, Gordon Kenneth B., Poulin Yves, Langley Richard G., Gottlieb Alice B., Dunn Meleana, Jahreis Angelika, Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis, 10.1001/archderm.143.6.719
  7. Leonardi C, J Drugs Dermatol, 9, 928 (2010)
  8. Mrowietz U., de Jong E.M.G.J., Kragballe K., Langley R., Nast A., Puig L., Reich K., Schmitt J., Warren R.B., A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis, 10.1111/jdv.12118
  9. Menter Alan, Korman Neil J., Elmets Craig A., Feldman Steven R., Gelfand Joel M., Gordon Kenneth B., Gottlieb Alice, Koo John Y.M., Lebwohl Mark, Leonardi Craig L., Lim Henry W., Van Voorhees Abby S., Beutner Karl R., Ryan Caitriona, Bhushan Reva, Guidelines of care for the management of psoriasis and psoriatic arthritis, 10.1016/j.jaad.2010.11.055
  10. Nast A, Update, 10, S1 (2012)
  11. Gelfand Joel M., Kimball Alexa B., Mostow Eliot N., Chiou Chiun-Fang, Patel Vaishali, Xia H. Amy, Freundlich Bruce, Stevens Seth R., Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment, 10.1111/j.1524-4733.2007.00251.x
  12. Gordon Kenneth B., Gottlieb Alice B., Leonardi Craig L., Elewski Boni E., Wang Andrea, Jahreis Angelika, Zitnik Ralph, Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy, 10.1080/09546630500472838
  13. Moore Angela, Gordon Kenneth B., Kang Sewon, Gottlieb Alice, Freundlich Bruce, Xia H. Amy, Stevens Seth R., A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis, 10.1016/j.jaad.2006.09.002
  14. Arcese Annalisa, Aste Nicola, Bettacchi Alberta, Camplone Germana, Cantoresi Franca, Caproni Marzia, DʼAmico Domenico, Fabbri Paolo, Filosa Giorgio, Galluccio Antonia, Hansel Katharina, Lisi Paolo, Micali Giuseppe, Musumeci Maria Letizia, Nicolini Massimiliano, Parodi Aurora, Patania Mario, Pezza Michele, Potenza Concetta, Richetta Antonio, Simonacci Marco, Trevisan Piergiusto, Valenti Giancarlo, Calvieri Stefano, Treating Psoriasis with Etanercept in Italian Clinical Practice : Prescribing Practices and Duration of Remission following Discontinuation, 10.2165/11537470-000000000-00000
  15. Daudén E, Griffiths CEM, Ortonne J-P, Kragballe K, Molta CT, Robertson D, Pedersen R, Estojak J, Boggs R, Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study : Patient-reported outcomes in psoriasis patients treated with etanercept, 10.1111/j.1468-3083.2009.03321.x
  16. Ortonne J.-P., Taïeb A., Ormerod A.D., Robertson D., Foehl J., Pedersen R., Molta C., Freundlich B., Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept, 10.1111/j.1365-2133.2009.09238.x
  17. Esposito Maria, Gisondi Paolo, Cassano Nicoletta, Babino Graziella, Cannizzaro Maria Vittoria, Ferrucci Giuliano, Chimenti Sergio, Giunta Alessandro, Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque-Type Psoriasis : Different Etanercept regimens for psoriasis, 10.1002/ddr.21190
  18. Strohal Robert, Chimenti Sergio, Vena Gino Antonio, Girolomoni Giampiero, Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence, 10.3109/09546634.2012.713462
  19. Herrera E., Alcaide A.J., Uso intermitente de etanercept en psoriasis, 10.1016/s0001-7310(10)70004-1
  20. Vena Gino A., Cassano Nicoletta, Piaserico Stefano, Conti Andrea, Girolomoni Giampiero, Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies, 10.3109/08923973.2012.692381
  21. Kimball Alexa B., Pariser David, Yamauchi Paul S., Menter Alan, Teller Craig F., Shi Yifei, Yong Mellissa, Creamer Kara, Hooper Michele, Aras Girish, Kricorian Gregory, Gelfand Joel M., OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis, 10.1016/j.jaad.2012.10.055
  22. Papp Kim A., Poulin Yves, Bissonnette Robert, Bourcier Marc, Toth Darryl, Rosoph Leslie, Poulin-Costello Melanie, Setterfield Mike, Syrotuik Jerry, Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population, 10.1016/j.jaad.2010.07.026
  23. Paller Amy S., Siegfried Elaine C., Eichenfield Lawrence F., Pariser David, Langley Richard G., Creamer Kara, Kricorian Greg, Long-term etanercept in pediatric patients with plaque psoriasis, 10.1016/j.jaad.2010.04.004
  24. Puig L., López A., Vilarrasa E., García I., Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points, 10.1111/jdv.12238
  25. Wolbink Gerrit J, Aarden Lucien A, Dijkmans BAC, Dealing with immunogenicity of biologicals: assessment and clinical relevance : , 10.1097/bor.0b013e328329ed8b
  26. Baert Filip, Noman Maja, Vermeire Severine, Van Assche Gert, D' Haens Geert, Carbonez An, Rutgeerts Paul, Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, 10.1056/nejmoa020888
  27. Radstake T R D J, Svenson M, Eijsbouts A M, van den Hoogen F H J, Enevold C, van Riel P L C M, Bendtzen K, Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, 10.1136/ard.2008.092833
  28. Maser Elana A., Villela Renata, Silverberg Mark S., Greenberg Gordon R., Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease, 10.1016/j.cgh.2006.06.025
  29. Ramirez-Fort MK, Clin Exp Rheumatol, 31, S63 (2013)
  30. Reich K., Wozel G., Zheng H., van Hoogstraten H.J.F., Flint L., Barker J., Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2), 10.1111/bjd.12404
  31. Papp K., Crowley J., Ortonne J.-P., Leu J., Okun M., Gupta S.R., Gu Y., Langley R.G., Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy : Retreatment with adalimumab for psoriasis, 10.1111/j.1365-2133.2010.10139.x
  32. Hsu Leeyen, Armstrong April W, Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response, 10.1586/1744666x.2013.836060
  33. Hsu L., Snodgrass B.T., Armstrong A.W., Antidrug antibodies in psoriasis: a systematic review, 10.1111/bjd.12654
  34. de Vries M K, van der Horst-Bruinsma I E, Nurmohamed M T, Aarden L A, Stapel S O, Peters M J L, van Denderen J C, Dijkmans B A C, Wolbink G J, Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis, 10.1136/ard.2008.089979
  35. Dore RK, Clin Exp Rheumatol, 25, 40 (2007)
  36. Mok C. C., van der Kleij D., Wolbink G. J., Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases, 10.1007/s10067-013-2336-x